Asset Details
Do you wish to reserve the book?
Differential immunogenicity in people living with HIV with varying CD4 levels after bivalent mRNA COVID-19 booster vaccination
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Differential immunogenicity in people living with HIV with varying CD4 levels after bivalent mRNA COVID-19 booster vaccination
Do you wish to request the book?
Differential immunogenicity in people living with HIV with varying CD4 levels after bivalent mRNA COVID-19 booster vaccination
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Differential immunogenicity in people living with HIV with varying CD4 levels after bivalent mRNA COVID-19 booster vaccination
2025
Overview
People living with HIV (PLWH) exhibit heterogeneous immune responses, influenced by varying degrees of immune deficiency and viral suppression. The efficacy of COVID-19 vaccines in this population remains underexplored, particularly in those with low CD4 counts. This study assessed the antibody response in PLWH with CD4 T-cell levels ≤200 cells/mm 3 compared to those with higher levels, following a bivalent mRNA COVID-19 vaccine booster. All participants were on effective Antiretroviral therapy (ART) with virologic suppression and had received the booster more than a year after their last vaccination. Participants with lower CD4 counts exhibited reduced baseline Anti-RBD IgG titers. However, significant increases in Anti-RBD IgG and surrogate virus neutralization test (sVNT) levels were observed across both CD4 groups post-booster. Despite lower Geometric mean titer (GMT) in the low CD4 group, this group achieved a higher post-boost Anti-RBD IgG Geometric mean ratio (GMR), indicating a robust vaccine response facilitated by effective ART. Nonetheless, cross-neutralization against the circulating XBB variant was limited. Although individuals in the low CD4 group exhibited reduced protection at baseline, they showed significant increase in Anti-RBD IgG and sVNT levels across all CD4 counts after receiving the bivalent COVID vaccine booster.
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
/ Antibodies, Neutralizing - immunology
/ Antibodies, Viral - immunology
/ Biological products industry
/ CD4-Positive T-Lymphocytes - immunology
/ COVID-19 - prevention & control
/ COVID-19 Vaccines - administration & dosage
/ COVID-19 Vaccines - immunology
/ Female
/ Highly active antiretroviral therapy
/ HIV Infections - drug therapy
/ Humans
/ Immunoglobulin G - immunology
/ Male
/ Medicine and Health Sciences
/ T cells
